Intelligent Tutoring System Intervention in Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer

Status: Active

Description

This trial studies an intelligent tutoring system intervention in enhancing genetic risk assessment in underserved Blacks and Latinas at risk of hereditary breast cancer. The intelligent tutoring system intervention (BRCA-gist) is a web-based tutoring system that provides education about hereditary breast and ovarian cancer. BRCA-gist may enhance the knowledge and use of genetic cancer risk assessments in at-risk Latina and Black women.

Eligibility Criteria

Inclusion Criteria

  • Participants will self-identify as Black and/or Latina
  • Participants will be at high risk of carrying HBOC mutation using personal/family cancer histories based on the National Comprehensive Cancer Network (NCCN) guidelines
  • Providers

Exclusion Criteria

  • Non-English proficiency
  • Not being able to provide informed consent

Locations & Contacts

District of Columbia

Washington
Comprehensive Breast Center
Status: Active
Contact: Lucile Lauren Adams-Campbell
Email: ng472@georgetown.edu
MedStar Georgetown University Hospital
Status: Active
Contact: Alejandra Hurtado de Mendoza
Phone: 202-687-8916
Email: ahd28@georgetown.edu
Nueva Vida, Inc.
Status: Active
Contact: Claudia Campos
Email: ccampos@nueva-vida.org

Virginia

Richmond
Virginia Commonwealth University / Massey Cancer Center
Status: Active
Contact: Vanessa L Sheppard
Email: Vanessa.Sheppard@vcuhealth.org

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. Adapt BRCA-gist.

II. Test the feasibility, acceptability, and efficacy of BRCA-gist intervention in a two-arm randomized controlled trial (RCT).

SECONDARY OBJECTIVES:

I. Explore differences by ethnicity and health literacy and assess emotional reactions to risk information to inform future affective-tailored interventions.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use the BRCA-gist web-based tutoring system over 90 minutes.

ARM II: Participants read information about hereditary breast and ovarian cancer (HBOC) and BRCA 1/2 on the National Cancer Institute's (NCI) website over 90 minutes.

After completion of study, participants are followed up at 3 months.

Trial Phase & Type

Trial Phase

No phase specified

Trial Type

Prevention

Lead Organization

Lead Organization
MedStar Georgetown University Hospital

Principal Investigator
Alejandra Hurtado de Mendoza

Trial IDs

Primary ID 2017-0524
Secondary IDs NCI-2019-01065
Clinicaltrials.gov ID NCT03511690